Journal Article Summary
The article discusses the challenges and opportunities related to sharing clinical and economic information about biopharmaceuticals before they receive FDA approval. This topic is important because timely access to such information can help healthcare decision-makers plan and budget for new medications, especially as the market sees an increase in high-cost drugs. Currently, federal laws and FDA regulations limit the exchange of this information, which can hinder effective health benefit design and financial forecasting.
To address these issues, the Academy of Managed Care Pharmacy (AMCP) held a Partnership Forum in September 2016, bringing together various stakeholders, including managed care professionals, biopharmaceutical representatives, and health economists. The forum focused on creating a new communication process called "preapproval information exchange" (PIE), which would allow for the sharing of relevant data from clinical trials and other sources 12-18 months before FDA approval. Participants discussed the standards for this information, who should access it, and how it should be disseminated, emphasizing the need for truthful and comprehensive data to support healthcare decision-making.
However, there are limitations to this proposed exchange of information, particularly regarding the need for new legislation to ensure that it complies with existing laws on preapproval promotion. Patients and caregivers should be aware that while this initiative aims to improve access to critical information, it is still in the discussion phase and may take time to implement. It is advisable for individuals to discuss any concerns or questions about new medications and their potential costs with their healthcare professionals, as they can provide guidance based on the latest information and regulations.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval. Journal of Managed Care & Specialty Pharmacy 2017. DOI: 10.18553/jmcp.2016.16366. PMID: 28025919. PMCID: PMC10398277.
Featured Pill Pals Product
Acetaminophen 500 MG Caplets ---1,000 Count --- Generic For Tylenol --- Major / Rugby --- Over The Counter
Acetaminophen 500 MG Caplets —1,000 Count — Generic For Tylenol — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
